Salidroside

Conclusion: When the relevant literature on the treatment of rodent AD models is combined with Sal, the therapeutic potential of Sal through multiple mechanisms was confirmed. However, further confirmation by higher quality studies, larger sample sizes, and more comprehensive outcome evaluations in clinical trials is needed in the future.

Conclusion: Recent advances in methods such as bioenhancers and nanotechnology to improve the bioavailability of PhGs are also summarized. The existing scientific gaps of PhGs in knowledge are also discussed, highlighting research directions in the future.

Conclusion: This systematic review confirms that the efficacy of dietary polyphenols is significantly composition-specific. Curcumin and salidroside can improve the course of COPD by regulating blood pressure, inflammation, and the coagulation pathway, supporting the hypothesis of "polyphenol targeting of metabolic-inflammatory networks". However, the possible negative effects of anthocyanins warn against ingredient heterogeneity. Clinical significance: Curcumin (200-500 mg/day) and tanshinone are recommended as adjuvant treatment options for COPD, but blind combination should be avoided; the safety of in

Conclusion: SAL provides preliminary preclinical evidence of renoprotection in DN models, potentially by modulating oxidative stress and inflammation. However, interpretation is constrained by high heterogeneity and possible small-study or publication effects. Anti-fibrotic effects, particularly TGF-β1, remain sensitive to methodology, necessitating caution. Rigorous, pre-registered animal trials are required to strengthen the evidence base.